Home › Encyclopedia › Lypressin: Research Status, Identity, and Trial Data
Research / Unapproved

Lypressin: Research Status, Identity, and Trial Data

Molecular formulaC46H65N13O12S2
Molecular weight1056.2 g/mol
Registered trials87
PubChem CID644076

Regulatory status

Lypressin is classified as an unapproved research compound. There is no approved drug label on file for this substance, and it is not available as a labeled pharmaceutical product.

What lypressin is

Lypressin is a peptide with the molecular formula C46H65N13O12S2 and a molecular weight of approximately 1056.2. It is cataloged under PubChem CID 644076. No FDA-approved indications, mechanism of action, or brand names are available for this compound because no approved label exists.

Trial footprint

A total of 87 trials are registered that reference this compound or closely related agents. Sample records in the registry include a completed study comparing terlipressin with albumin, midodrine with albumin, and albumin alone for preventing circulatory dysfunction after paracentesis in cirrhosis. Another completed trial examined intramyometrial injection of terlipressin versus carbitocin on hemoglobin levels and blood loss during myomectomy procedures. A third trial, with unknown status, studied continuous terlipressin infusion in septic shock. These records describe study design and status only, not outcomes or conclusions.

FAQ

Is lypressin an FDA-approved drug?
No. Lypressin is classified as an unapproved research compound, and no FDA drug label is on file for it. It is not available as an approved pharmaceutical product.
What is the chemical identity of lypressin?
Lypressin is a peptide with the molecular formula C46H65N13O12S2 and a molecular weight of approximately 1056.2. It is listed in PubChem under CID 644076.
How many clinical trials reference lypressin?
Registry records show a total of 87 trials referencing this compound or closely related agents. Sample trials include studies in cirrhosis, myomectomy, and septic shock settings.
Do the available trials show that lypressin works for these conditions?
The trial records describe study design, phase, and completion status only. They do not provide outcome data or conclusions about effectiveness.
Are there reported side effects for lypressin?
No adverse event report data is currently available for this compound in the dataset reviewed.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem ClinicalTrials.gov

Updated 2026-11-07